Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: A double-blind, randomized, placebo-controlled trial

Head and Neck

Volumn 37, Issue 6, 2015, Pages 783-787

  Riss, Dominik ^a   Burian, Martin ^b   Wolf, Axel ^a   Kranebitter, Veronika ^a   Kaider, Alexandra ^a   Arnoldner, Christoph ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Krankenhaus der Barmherzigen Schwestern Linz   (Austria)

Author keywords

avastin; hereditary hemorrhagic telangiectasia (HHT); Rendu Osler Weber syndrome

Indexed keywords

BEVACIZUMAB; PLACEBO;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; ELEVATED BLOOD PRESSURE; EPISTAXIS; FEMALE; HEART PALPITATION; HUMAN; MALE; MIDDLE AGED; MYALGIA; NECK PAIN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENDU OSLER WEBER DISEASE; RHINITIS; SINGLE BLIND PROCEDURE; SLEEP DISORDER; THROMBOEMBOLISM; VISUAL ANALOG SCALE; ADOLESCENT; AUSTRIA; COMPARATIVE STUDY; COMPLICATION; DRUG EFFECTS; FOLLOW UP; INTRALESIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; NOSE MUCOSA; PAIN MEASUREMENT; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUSTRIA; BEVACIZUMAB; DOUBLE-BLIND METHOD; EPISTAXIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; NASAL MUCOSA; PAIN MEASUREMENT; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929931605     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23655     Document Type: Article

References (9)

1. Shovlin CL, Guttmacher AE, Buscarini E, et al., Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000; 91: 66-67.
2. Sadick H, Riedel F, Naim R, et al., Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 2005; 90: 818-828.
3. Flieger D, Hainke S, Fischbach W,. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol 2006; 85: 631-632.
4. Simonds J, Miller F, Mandel J, Davidson TM,. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 2009; 119: 988-992.
5. Karnezis TT, Davidson TM,. Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy. Laryngoscope 2012; 122: 495-497.
6. Hoag JB, Terry P, Mitchell S, Reh D, Merlo CA,. An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope 2010; 120: 838-843.
7. Karnezis TT, Davidson TM,. Efficacy of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 2011; 121: 636-638.
8. Dheyauldeen S, Østertun Geirdal A, Osnes T, Vartdal LS, Dollner R,. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose. Laryngoscope 2012; 122: 1210-1214.
9. Chen S IV, Karnezis T, Davidson TM,. Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 2011; 121: 644-646.